

IFW

Patent Application  
Attorney Docket No. PC25339A

hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 12th day of October, 2005.

By

*Rebecca Pesantez*  
(Signature of person mailing)  
Rebecca Pesantez

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: KATH ET AL.

APPLICATION NO.: 10/734,039

: Examiner: Rao, Deepak R.

FILING DATE: DECEMBER 11, 2003

: Group Art Unit: 1624

TITLE: COMPOUNDS FOR THE TREATMENT  
OF ABNORMAL CELL GROWTH

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicants, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.


It is requested that the references listed on the attached form PTO/FB/A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: October 12, 2005



Pamela C. Ancona, Ph.D.  
Attorney for Applicants  
Reg. No. 41,494

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212)733-6031

**SUPPLEMENTARY INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

ATTY. DOCKET NO. PC25339A

SERIAL NO. 10/734,039

APPLICANT John C. Kath et al.

FILING DATE December 11, 2003

GROUP 1624

U.S. PATENT DOCUMENTS														
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS														
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	0	0	0	1	2	4	8	5	03/09/00	WO	C07D	239/48		
	0	2	0	5	9	1	1	0	08/01/02	WO	C07D	403/12		
	0	3	0	2	0	2	7	6	03/13/03	WO	A61K	31/4704		
	0	4	0	4	6	1	1	8	06/03/04	WO	C07D	239/00		
	0	4	0	5	6	7	8	6	07/08/04	WO	C07D	239/00		
	0	4	0	5	6	8	0	7	07/08/04	WO	C07D	403/12		

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

			Diringer et al., Journal of Medicinal Chemistry, Vol. 13, No. 1, pp. 151-152 (1970); and
			Supuran et al., Expert Opin. Ther. Patents, Vol. 14, No. 1, pp. 35-53 (2004).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.